PGT-A in Thailand Your guide to cost, top specialists & hospitals

Our partner clinics have in-house or closely partnered genetics laboratories equipped with NGS platforms for PGT-A analysis. Their embryologists perform trophectoderm biopsies routinely with documented low damage rates. The combination of experienced biopsy technique and reliable analysis produces consistent, actionable results.

PGT-A results require expert interpretation, particularly mosaic results. Our partner clinics provide genetic counselling from qualified professionals who explain the clinical significance of each result and help you make informed decisions. This is not a generic lab report; it is a personalised consultation.

Ask about the clinic's biopsy damage rate (it should be very low). Confirm they use NGS technology, not older aCGH platforms. Check whether genetic counselling is included in the PGT-A package. Ask about turnaround time; one to two weeks is standard. And confirm the clinic handles mosaic results with nuance rather than blanket rejection of all mosaic embryos.

Per-transfer implantation and miscarriage figures often look better when a euploid embryo is selected, particularly with advanced maternal age where aneuploidy rates rise. The more honest measure, however, is cumulative live-birth rate per egg retrieval, which counts every transfer of every embryo from one cycle. On that measure, the STAR trial (2019) found no improvement for unselected patients, and other studies show differences narrow or disappear. The UK HFEA rates PGT-A red for improving the chances of having a baby for most patients on its add-on traffic-light system.¹ PGT-A can help avoid transferring embryos with very low implantation potential and may reduce the time to a successful transfer, but it does not reliably increase the chance of taking a baby home from a given egg retrieval for most patients¹.

PGT-A screens for chromosome number, not single-gene disorders (that requires PGT-M). It does not assess embryo quality in terms of mitochondrial function, metabolic activity, or other developmental factors. A euploid embryo still needs a receptive uterine environment and correct transfer timing to implant. PGT-A improves the odds; it does not guarantee success.²

PGT-A in Thailand costs between $2,000 and $3,600 for testing of up to eight embryos. Additional per-embryo fees apply above this number. The cost covers genetic counselling, the biopsy procedure, NGS analysis, results consultation, and a written report with recommendations.

The PGT-A fee includes genetic counselling before testing, the embryo biopsy performed by the embryology team, the genetic analysis using next-generation sequencing, a results consultation, and a comprehensive written report. If you have more than eight embryos to test, additional per-embryo fees apply. The IVF cycle itself is priced separately.

The number of embryos tested is the main variable. The base fee typically covers up to eight embryos, with additional charges per embryo above that threshold. If PGT-M (single-gene testing) is combined with PGT-A on the same biopsy, additional fees apply for the PGT-M component. The IVF cycle cost, medication, and embryo freezing are all separate line items.

Pricing varies by the complexity and scope of the procedure. Typical ranges at our partner hospitals in Thailand:

• PGT-A for up to 4 embryos: $2,000–$2,500. Biopsy and chromosomal screening of a small embryo cohort
• PGT-A for 5–8 embryos: $2,500–$3,000. Mid-range cohort with per-embryo cost reduction
• PGT-A for 9 or more embryos: $3,000–$3,600. Large cohort testing at the lowest per-embryo rate

Exact pricing is confirmed after your consultation and treatment plan are finalised.

PGT-A in Thailand costs 50–70% less than equivalent testing in the US ($5,000–$9,000), Australia (A$4,400–A$8,000), and UK (£4,000–£7,000). Given the significant impact PGT-A has on per-transfer success rates and miscarriage reduction, the lower Thai pricing makes it a practical addition to any IVF cycle rather than an expensive upgrade.

No additional stay is needed beyond your IVF cycle. The biopsy happens during the standard embryo culture period. Results take one to two weeks, during which you can return home. You will return for a frozen embryo transfer (a separate visit of five to seven days) once results confirm a euploid embryo is available.

This is a possibility, particularly for women over 40 where aneuploidy rates are higher. If all tested embryos are aneuploid, options include another IVF cycle to produce more embryos, using donor eggs, or other treatment pathways. Knowing the result in advance prevents you from transferring embryos with very low implantation potential, saving time, money, and the emotional toll of an unsuccessful transfer.

Evidence for routine PGT-A in younger patients is weak. The STAR trial (2019) found no live-birth improvement per started cycle for unselected patients, and the HFEA rates PGT-A red for improving the chance of a baby for most patients and grey in older women, with the strongest signal in specific clinical contexts such as recurrent miscarriage or repeated implantation failure. For most patients under 35 with a good embryo cohort, PGT-A is unlikely to change whether you take a baby home. It may still be considered to shorten time-to-pregnancy in a specific situation, but it is a shared decision with your specialist, not a default upgrade.

Yes. PGT-A is performed at licensed fertility clinics using the same biopsy equipment and NGS platforms found in top genetics laboratories worldwide. Our partner clinics employ experienced embryologists with documented biopsy proficiency and work with accredited genetics labs for analysis. Quality-control measures meet international standards.

PGT-A has high accuracy for detecting whole-chromosome aneuploidy, the most common cause of implantation failure and early miscarriage. However, it is not perfect. False positives (an embryo classified as aneuploid that is actually normal) and false negatives (the opposite) can occur, though both are rare. Mosaicism, where a biopsy sample contains a mix of normal and abnormal cells, adds complexity. These limitations are discussed in your genetic counselling session.

A mosaic embryo contains a mixture of chromosomally normal and abnormal cells. Mosaicism is detected in a minority of biopsied embryos, and the reported rate varies widely between laboratories.³ Handling mosaic results is one of the genuinely uncertain areas of PGT-A: the biopsy samples only a few outer cells and may not reflect the inner cell mass, healthy births have been reported from transferred low-level mosaics, and professional guidance such as PGDIS recommendations continues to evolve. It is not a binary keep-or-discard decision. Genetic counselling weighs the level and type of mosaicism against the alternative embryos available to you and the wider clinical picture, and the decision rests with you.

The biopsy is performed on day five or six of embryo culture, within your standard IVF stay. Embryos are vitrified immediately after biopsy. You can return home while results are processed over one to two weeks. Once results confirm a euploid embryo, you return for a frozen embryo transfer, a separate visit of five to seven days.

PGT-A adds cost but can save money overall by reducing the number of unsuccessful transfers. It is most clearly beneficial for women over 35, those with recurrent miscarriage, and those who have experienced repeated implantation failure. For younger patients with multiple good-quality embryos, the added value is smaller, but the confidence of knowing you are transferring a chromosomally normal embryo may still be worthwhile.

If you carry a known genetic condition, PGT-M (testing for a specific gene) can be performed on the same biopsy as PGT-A. This screens embryos for both chromosomal abnormalities and the specific inherited condition simultaneously. The combined approach gives you the most comprehensive information about each embryo before transfer.